Edesa Biotech, Inc. (EDSA)
Nasdaq · Healthcare · Biotechnology
$3.91+1.30%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $52.8M
- 52-week range
- $0.72 – $20.32
- 52-week change
- +40.36%
- EPS (trailing)
- −$1.72
Fiscal year to Sep 2025
- Net income
- −$7.2M
From the company’s annual report on SEC EDGAR.
About Edesa Biotech, Inc.
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B.
Headquarters: Markham, Canada · 17 employees · edesabiotech.com